Physician profile
Hung Dang
NPI 1568403889
$2,587.70
in general payments reported to CMS, 2019-2025
18 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $497 · 2021: $168 · 2022: $268 · 2023: $248 · 2024: $198 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $837.43 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $375.22 | 2020-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $343.96 | 2024-2025 | |
| Amgen INC. | $286.49 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $143.70 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.08 | 2019-2025 | Jardiance, Tradjenta |
| Sanofi Pasteur INC. | $105.05 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $79.43 | 2021-2023 | |
| Pfizer INC. | $53.90 | 2020-2021 | |
| Optinose US, INC. | $40.50 | 2019 | |
| Dexcom, INC. | $36.06 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.00 | 2019 | |
| Gilead Sciences, INC. | $23.91 | 2020 | |
| Corcept Therapeutics | $21.03 | 2025 | Korlym |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.96 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.00 | 2019 | |
| Merck Sharp & Dohme LLC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.